

# Stanford

---



## Joel Neal, MD, PhD

Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center  
Medicine - Oncology

### CLINICAL OFFICES

- **Stanford Comprehensive Cancer Center**

875 Blake Wilbur Dr Rm 2220

MC 6560

Stanford, CA 94305

**Tel** (650) 498-6000

**Fax** (650) 498-5800

### ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Administrative Assistant

**Tel** 650-725-3081

### Bio

---

#### BIO

Dr. Neal holds a medical degree and a doctoral degree in Tumor Cell Biology from Northwestern University in Chicago, Illinois. Subsequently, he completed a fellowship in oncology, rotating through the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. He is currently an Assistant Professor in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Neal's primary clinical interest is in thoracic oncology. In addition to maintaining an active practice, he focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer and mesothelioma. He has published dozens of articles in the field of thoracic oncology, including in *Lancet Oncology*, *Nature Medicine*, and the *Journal of Clinical Oncology*. He is a member of the International Association of the Study of Lung Cancer (IASLC), is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group, and has presented at a number of American Society of Clinical Oncology (ASCO) annual meetings.

#### CLINICAL FOCUS

- Cancer > Thoracic Oncology
- Thoracic Oncology
- Lung Cancer
- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Assistant Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute

#### PROFESSIONAL EDUCATION

- Residency: Beth Israel Deaconess Medical Center Internal Medicine Residency (2007) MA
- Medical Education: Northwestern University Feinberg School of Medicine (2004) IL
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2010) MA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2010)

## LINKS

- Publications: <https://www.ncbi.nlm.nih.gov/pubmed/?term=neal%2C+joel+w>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

I am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.

### CLINICAL TRIALS

- A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors, Recruiting
- A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC), Recruiting
- Crizotinib in Treating Patients With Stage IB-III A Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial), Recruiting
- Erlotinib Hydrochloride in Treating Patients With Stage IB-III A Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial), Recruiting
- Genetic Testing in Screening Patients With Stage IB-III A Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial), Recruiting
- Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients, Recruiting
- MAGE A10####T for Advanced NSCLC, Recruiting
- Molecular Analysis of Thoracic Malignancies, Recruiting
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor, Recruiting
- Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer, Recruiting
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer, Recruiting
- Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy, Recruiting
- SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer, Recruiting
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination, Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors, Not Recruiting
- A Phase 1/2 Study to Evaluate MEDI4736, Not Recruiting
- A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies, Not Recruiting
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR], Not Recruiting
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers, Not Recruiting
- A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies, Not Recruiting

- A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck, Not Recruiting
- A Study of Onartuzumab (MetMab) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer, Not Recruiting
- A Study of Onartuzumab (MetMab) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer, Not Recruiting
- Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation, Not Recruiting
- An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene, Not Recruiting
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026), Not Recruiting
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer, Not Recruiting
- BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery, Not Recruiting
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery, Not Recruiting
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer, Not Recruiting
- Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas, Not Recruiting
- Erlotinib and Mometinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC), Not Recruiting
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer, Not Recruiting
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR, Not Recruiting
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations, Not Recruiting
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC, Not Recruiting
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib, Not Recruiting
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer, Not Recruiting
- Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer, Not Recruiting
- PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients, Not Recruiting
- Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy, Not Recruiting
- Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC), Not Recruiting
- Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors, Not Recruiting
- Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer, Not Recruiting
- Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer, Not Recruiting
- Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma, Not Recruiting
- Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer, Not Recruiting
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer, Not Recruiting
- Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours, Not Recruiting
- Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors, Not Recruiting
- Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010), Not Recruiting

- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010], Not Recruiting
- Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients, Not Recruiting
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer, Not Recruiting
- TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy, Not Recruiting
- Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141), Not Recruiting
- Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Not Recruiting

## Teaching

---

### COURSES

#### 2018-19

- Cellular and Clinical Aspects of Cancer: CBIO 242 (Spr)

#### 2017-18

- Cellular and Clinical Aspects of Cancer: CBIO 242 (Spr)

## Publications

---

### PUBLICATIONS

- **EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., Del Prete, S., Wurtz, A., Farago, et al  
2018: JCO1801585
- **SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., Evans, T. L., Costa, D. B., Wakelee, H. A., Heist, R. S., Shapiro, M. A., Muzikansky, A., Murthy, et al  
2018: JCO1800131
- **Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.** *Journal of global oncology*  
Nguyen, K. H., Stehr, H., Zhou, L., Nguyen, A., Hiep, P. N., Van Cau, N., Duy, P. C., Thorp, R., Wakelee, H. A., Diehn, M., Neal, J. W.  
2018: 1-9
- **Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.** *Clinical lung cancer*  
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., Wakelee, H. A.  
2018
- **Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*  
Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., Wakelee, H. A.  
2018
- **Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data**  
Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., Neal, J., Harrow, K., Holzhausen, A., Liang, C., Dukart, G., Horn, L.  
ELSEVIER SCIENCE INC.2018: S156
- **Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.** *Lung cancer (Amsterdam, Netherlands)*  
Wang, S. X., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., Neal, J. W.  
2018; 122: 187-91

- **The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*  
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A., Gandhi, L., Garon, E. B., Hellmann, M. D., Hirsch, F. R., Malik, et al  
2018; 6: 75
- **Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Zweig, J. R., Neal, J. W.  
2018: JCO2018788554
- **Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study** *CLINICAL CANCER RESEARCH*  
Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A., Waqar, S. N., Gitlitz, B. J., Sanborn, R. E., Whisenant, J. G., Du, L., Neal, J. W., Gockerman, J. P., Dukart, et al  
2018; 24 (12): 2771–79
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer**  
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., Newman, A. M., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H., Das, et al  
ELSEVIER SCIENCE INC.2018: E1–E2
- **Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors** *JOURNAL OF THORACIC IMAGING*  
Padda, S. K., Terrone, D., Tian, L., Khuong, A., Neal, J. W., Riess, J. W., Berry, M. F., Hoang, C. D., Burt, B. M., Leung, A. N., Schwartz, E. J., Shrager, J. B., Wakelee, et al  
2018; 33 (3): 176–83
- **Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction**  
Hirotsu, K., Subramanian, A., Neal, J., Li, S., Pugliese, S., Kwong, B.  
ELSEVIER SCIENCE INC.2018: S176
- **Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer** *LUNG CANCER*  
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., Rosovsky, R. P., Lilenbaum, R. C., Bastos, B. R., Huang, C., Johnson, M. L., Hesketh, P. J., Subramaniam, et al  
2018; 117: 44–49
- **Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.** *Clinical lung cancer*  
Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., Diehn, M., Loo, B. W., Gensheimer, M. F.  
2018
- **Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.** *The oncologist*  
Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., Neal, J. W.  
2018
- **Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma**  
Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A. A., Wakelee, H., Neal, J. W., Backhus, L. M., Shrager, J. B.  
MOSBY-ELSEVIER.2017: 2092-+
- **Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer** *RADIOTHERAPY AND ONCOLOGY*  
Gensheimer, M. F., Hong, J. C., Chang-Halpeny, C., Zhu, H., Eclow, N. W., To, J., Murphy, J. D., Wakelee, H. A., Neal, J. W., Le, Q., Hara, W. Y., Quon, A., Maxim, et al  
2017; 125 (2): 338–43
- **Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma**  
Yang, S., Steiner, D., Berry, G. J., Neal, J. W., Zehnder, J. L., Kunder, C. A.  
ELSEVIER SCIENCE INC.2017: 1009–10
- **Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer**

- Xiang, M., Gensheimer, M. F., Maxim, P. G., Wakelee, H. A., Neal, J. W., Diehn, M., Loo, B. W.  
ELSEVIER SCIENCE INC.2017: E504
- **Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer**  
Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclov, N., To, J., Murphy, J. D., Wakelee, H. A., Neal, J. W., Le, Q. T., Hara, W., Quon, A., Maxim, P. G., Graves, et al  
ELSEVIER SCIENCE INC.2017: E456
  - **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer**  
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H. R., Das, M., Padda, S., Loo, et al  
ELSEVIER SCIENCE INC.2017: S20–S21
  - **Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome**  
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., Carter, J. N., Azad, T. D., Padda, S., Gensheimer, M. F., Wakelee, H. A., Neal, J. W., Loo, et al  
ELSEVIER SCIENCE INC.2017: S1–S2
  - **Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer**  
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C. L., Kurtz, D. M., Gensheimer, M. F., Shrager, J. B., Wakelee, et al  
ELSEVIER SCIENCE INC.2017: S114
  - **Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.** *Neurosurgery*  
Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., Hayden Gephart, M.  
2017
  - **The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer** *CANCER*  
Chuang, J. C., Neal, J. W.  
2017; 123 (15): 2798–2801
  - **Novel systemic therapy against malignant pleural mesothelioma** *TRANSLATIONAL LUNG CANCER RESEARCH*  
Mancuso, M. R., Neal, J. W.  
2017; 6 (3): 295–314
  - **Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging**  
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Zhou, L., Liu, C., Scherer, F., Kurtz, D. M., Esfahani, M. S., Say, C., Carter, et al  
ELSEVIER SCIENCE INC.2017: E4
  - **Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry** *JOURNAL OF CLINICAL ONCOLOGY*  
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., Remon-Masip, J., Janne, P. A., Awad, et al  
2017; 35 (13): 1403-?
  - **Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib.** *International journal of radiation oncology, biology, physics*  
Wang, S. X., Zhang, B., Wakelee, H. A., Diehn, M., Kunder, C., Neal, J. W.  
2017; 98 (1): 239-?
  - **CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)**  
Reckamp, K. L., Wakelee, H. A., Patel, S., Blumenschein, G., Neal, J. W., Gitlitz, B., Waqar, S. N., Tan, F., Harrow, K., Horn, L.  
OXFORD UNIV PRESS.2017
  - **Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.** *Molecular diagnosis & therapy*  
Costa, H. A., Neal, J. W., Bustamante, C. D., Zehnder, J. L.  
2017
  - **Elusive Target of Angiogenesis in Small-Cell Lung Cancer.** *Journal of clinical oncology*

- Neal, J. W., Wakelee, H. A.  
2017: JCO2016716084-?
- **ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.** *Journal of thoracic oncology*  
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., Wakelee, H. A., Neal, J. W.  
2017
  - **Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.** *International journal of radiation oncology, biology, physics*  
Choi, C. Y., Wakelee, H. A., Neal, J. W., Pinder-Schenck, M. C., Yu, H. M., Chang, S. D., Adler, J. R., Modlin, L. A., Harsh, G. R., Soltys, S. G.  
2017; 99 (1): 16–21
  - **Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer** *JCO: Clinical Cancer Informatics*  
Bui, N., Henry, S., Wood, D., Wakelee, H. A., Neal, J. W.  
2017
  - **Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.** *Cancer discovery*  
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., Scherer, F., Kurtz, D. M., Say, et al  
2017
  - **Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer**  
Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., Carter, J., Zhou, L., West, R., Shrager, J., Neal, J., Wakelee, H., Loo, et al  
ELSEVIER SCIENCE INC.2017: S445
  - **A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma**  
Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J. W., Camidge, D., Perol, M., Ou, S., Liu, S., Yu, H., Socinski, M., Mekhai, et al  
ELSEVIER SCIENCE INC.2017: S384–S385
  - **Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)**  
Doebele, R., Horn, L., Spira, A., Piotrowska, Z., Costa, D., Neal, J., Reichmann, W., Kerstein, D., Li, S., Janne, P.  
ELSEVIER SCIENCE INC.2017: S1072–S1073
  - **A Phase Ib Study of Erlotinib and Mometinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer**  
Padda, S., Reckamp, K., Koczywas, M., Neal, J., Brachmann, C., Kawashima, J., Kong, S., Xin, Y., Huang, D., Wakelee, H.  
ELSEVIER SCIENCE INC.2017: S1070–S1071
  - **A Phase II Study of Ertinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer**  
Nagpal, S., Wakelee, H., Padda, S., Bertrand, S., Acevedo, B., Tisch, A., Pagtama, J., Soltys, S., Neal, J.  
ELSEVIER SCIENCE INC.2017: S940
  - **Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC**  
Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., Waqar, S., Neal, J., Gockerman, J., Harrow, K., Dukart, G., Liang, C., Gibbons, et al  
ELSEVIER SCIENCE INC.2017: S1159
  - **Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting*  
El-Deiry, W. S., Taylor, B., Neal, J. W.  
2017; 37: e8–e15
  - **Molecular profiling of single circulating tumor cells from lung cancer patients** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Park, S., Wong, D. J., Ooi, C. C., Kurtz, D. M., Vermesh, O., Aalipour, A., Suh, S., Pian, K. L., Chabon, J. J., Lee, S. H., Jamali, M., Say, C., Carter, et al  
2016; 113 (52): E8379–E8386
  - **Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial** *LANCET ONCOLOGY*  
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., Owonikoko, T. K., Stella, P. J., Steen, et al  
2016; 17 (12): 1661–1671



- **Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.** *Nature communications*  
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al  
2016; 7: 13513-?
- **PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology.** *Journal of thoracic oncology*  
Wang, S. X., Zhang, B. M., Wakelee, H., Diehn, M., Kunder, C. A., Neal, J. W.  
2016; 11 (11S): S312-S313
- **PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology.** *Journal of thoracic oncology*  
Salahudeen, A., De La O, S., Padda, S. K., Neal, J. W., Wakelee, H., Kuo, C.  
2016; 11 (11S): S282-?
- **PS01.04: A Phase II Study of Etrinetecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.** *Journal of thoracic oncology*  
Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., Pagtama, J. Y., Soltys, S. G., Nagpal, S.  
2016; 11 (11S): S271-S272
- **MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology.** *Journal of thoracic oncology*  
Horn, L., Wakelee, H., Reckamp, K. L., Blumenschein, G., Infante, J. R., Carter, C. A., Waqar, S. N., Neal, J. W., Harrow, K., Gockerman, J. P., Dukart, G., Liang, C., Gibbons, et al  
2016; 11 (11S): S256-S257
- **Rociletinib-associated cataracts in EGFR-mutant NSCLC**  
Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., Neal, J., Spiegel, M., Solomon, B., Yu, H., Ou, S. I., Papadimitrakopoulou, V. A., Gadgeel, et al  
OXFORD UNIV PRESS.2016
- **CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer**  
Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., Aggarwal, S., Carter, J. N., West, R. B., Neal, J. W., Wakelee, H. A., Loo, B. W., Alizadeh, et al  
ELSEVIER SCIENCE INC.2016: S41-S42
- **Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)**  
Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., Gitlitz, B. J., Infante, J. R., Sanborn, R. E., Neal, J., Gockerman, J. P., Dukart, G., Harrow, et al  
OXFORD UNIV PRESS.2016
- **Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.** *Journal of oncology practice / American Society of Clinical Oncology*  
Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., Hofmann, L. V., Neal, J. W., Telli, M. L.  
2016; 12 (8): 763-764
- **Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.** *Clinical therapeutics*  
Chuang, J. C., Shrager, J. B., Wakelee, H. A., Neal, J. W.  
2016; 38 (7): 1567-1576
- **Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients** *NATURE COMMUNICATIONS*  
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., Harding, T. C., Durkin, K. A., Otterson, et al  
2016; 7
- **Integrated digital error suppression for improved detection of circulating tumor DNA** *NATURE BIOTECHNOLOGY*  
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., Zhou, L., Carter, J. N., West, et al  
2016; 34 (5): 547-555



- **Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.** *Clinical lung cancer*  
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., Diehn, M., Wakelee, H. A.  
2016; 17 (2): e17-21
- **Pruritus as a Paraneoplastic Symptom of Thymoma** *JOURNAL OF THORACIC ONCOLOGY*  
Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J., Kwong, B. Y., Liang, Y., Schwartz, E. J., Loo, B. W., Neal, J. W., Hardy, R., Wakelee, H. A.  
2015; 10 (11): E110-E112
- **Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial**  
Modlin, L. A., Choi, C. H., Gibbs, I. C., Wakelee, H. A., Neal, J., Pinder-Schenck, M. C., Chang, S. D., Adler, J. R., Harsh, G. R., Soltys, S. G.  
ELSEVIER SCIENCE INC.2015: S178
- **Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.** *Translational lung cancer research*  
Chuang, J. C., Neal, J. W.  
2015; 4 (5): 639-641
- **Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.** *American journal of ophthalmology*  
Leung, L. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., Marmor, M. F.  
2015; 160 (4): 799-805 e1
- **Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.** *Lung cancer*  
Chuang, J. C., Neal, J. W., Niu, X., Wakelee, H. A.  
2015; 90 (1): 1-7
- **Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.** *American journal of ophthalmology*  
Leung, L. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., Marmor, M. F.  
2015; 160 (4): 799-805 e1
- **Management of Dermatologic Complications of Lung Cancer Therapies.** *Current treatment options in oncology*  
Pugliese, S. B., Neal, J. W., Kwong, B. Y.  
2015; 16 (10): 368-?
- **Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction** *LUNG CANCER*  
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., Wakelee, H. A.  
2015; 89 (3): 280-286
- **A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512**  
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., Ramalingam, S. S.  
ELSEVIER SCIENCE INC.2015: S373
- **Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies**  
Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., Ramchandran, K. J., Gubens, M. A., Neal, J. W., Loehrer, P. J.  
ELSEVIER SCIENCE INC.2015: S195
- **VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer**  
Padda, S. K., Lara, P., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H., Zhou, L. Y., Subramaniam, D. S., Leach, J. W., Wax, M. B., Neal, J. W., Clary, D. O., Goodman, et al  
ELSEVIER SCIENCE INC.2015: S291
- **Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies**  
Chuang, J., Neal, J. W., Wakelee, H. A.  
ELSEVIER SCIENCE INC.2015: S549
- **Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma**  
Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., Berry, M., Leung, A. N., Schwartz, E. J., Shrager, J. B., Wakelee, H. A.  
ELSEVIER SCIENCE INC.2015: S196
- **Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*

- Liang, Y., Wakelee, H. A., Neal, J. W.  
2015; 16 (5): 366-373
- **Improved survival among lung cancer patients taking antidepressants**  
Zingone, A., Brown, D., Bowman, E., Vidal, O., Neal, J., Sage, J., Ryan, B. M.  
AMER ASSOC CANCER RESEARCH.2015
  - **Heterogeneity Underlies the Emergence of EGFR T790M Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.** *Cancer discovery*  
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., Digumarthy, S., Muzikansky, A., Raponi, et al  
2015; 5 (7): 713-722
  - **Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).**  
Neal, J. W., Dahlberg, S., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D., Ramalingam, S. S.  
AMER SOC CLINICAL ONCOLOGY.2015
  - **Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).**  
Wakelee, H. A., Padda, S., Burns, M., Spittler, A., Riess, J., San Pedro-Salcedo, M., Ramchandran, K., Gubens, M. A., Neal, J. W., Loehrer, P. J.  
AMER SOC CLINICAL ONCOLOGY.2015
  - **Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*  
Sequist, L. V., Soria, J., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., SOLOMON, B. J., Oxnard, G. R., Dziadziuszko, R., Aisner, D. L., Doebele, R. C., Galasso, et al  
2015; 372 (18): 1700-1709
  - **Developing biomarker-specific end points in lung cancer clinical trials** *NATURE REVIEWS CLINICAL ONCOLOGY*  
Neal, J. W., Gainor, J. F., Shaw, A. T.  
2015; 12 (3): 135-146
  - **Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.** *Journal of thoracic oncology*  
Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., West, R. B., Wakelee, H. A.  
2015; 10 (3): 500-508
  - **Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.** *Proceedings of the National Academy of Sciences of the United States of America*  
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidiias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., Gandhi, L., Lynch, T. J., Engelman, et al  
2015; 112 (5): 1547-1552
  - **GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.** *Anticancer research*  
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., Wakelee, H. A.  
2015; 35 (2): 669-676
  - **GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray.** *Anticancer research*  
Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., Wakelee, H. A.  
2015; 35 (2): 669-676
  - **Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.** *Lung cancer*  
Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., Wakelee, H. A.  
2015; 87 (1): 34-38
  - **Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis.** *Annals of thoracic surgery*  
Hamaji, M., Neal, J. W., Burt, B. M.  
2015; 99 (1): e7-9
  - **Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing**  
Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, A.  
ELSEVIER SCIENCE INC.2014: S75

- **Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)**  
Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., Rosovsky, R., Lilienbaum, R., Bastos, B. R., Huang, C., Johnson, M. L., Hasketh, P. J., Subramaniam, et al  
ELSEVIER SCIENCE INC.2014: S36
- **Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.** *Nature reviews. Clinical oncology*  
Neal, J. W., Sledge, G. W.  
2014; 11 (11): 627-628
- **Review of the current targeted therapies for non-small-cell lung cancer.** *World journal of clinical oncology*  
Nguyen, K. H., Neal, J. W., Wakelee, H.  
2014; 5 (4): 576-587
- **A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors**  
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., Zmoos, A., Vaka, D., Tran, K. T., Zhou, M., Krasinska, K., Riess, J. W., Neal, et al  
AMER ASSOC CANCER RESEARCH.2014
- **PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY**  
Liang, Y., Padda, S., Riess, J. W., West, R., Neal, J. W., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2014: S226
- **Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC**  
Modlin, L. A., Bratman, S. V., Newman, A. M., Eclov, N. W., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Alizadeh, A. A., Diehn, M.  
ELSEVIER SCIENCE INC.2014: S812
- **COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA**  
Padda, S., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., Hoang, C. D., Burt, B. M., Leung, A. N., Shrager, J. B., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2014: S222
- **PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA**  
Padda, S., Pagtama, J. Y., Tisch, A. H., Neal, J. W., Riess, J. W., Loo, B. W., Hardy, R., Shrager, J. B., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2014: S240-S241
- **PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)**  
Padda, S., Riess, J. W., Schwartz, E., Tian, L., Kohrt, H., Neal, J. W., West, R., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2014: S212
- **Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA)**  
Padda, S., Riess, J., Schwartz, E., Tian, L., Kohrt, H., Neal, J. W., Natkunam, Y., West, R. B., Wakelee, H. A.  
AMER SOC CLINICAL ONCOLOGY.2014
- **SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.**  
Pennell, N. A., Neal, J. W., Chافت, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., Evans, T. L., Costa, D., Rosovsky, R., Wakelee, H. A., Heist, R., Shaw, A., Temel, et al  
AMER SOC CLINICAL ONCOLOGY.2014
- **Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.**  
Bratman, S., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., Shrager, J. B., Loo, B. W., Diehn, M., Alizadeh, A. A.  
AMER SOC CLINICAL ONCOLOGY.2014
- **A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)**  
Neal, J. W., Wakelee, H. A., Feliciano, J., Goldberg, S. B., Morgensztern, D., Das, M., Heist, R., Lennes, I., Muzikansky, A., Edelman, M. J., Gettinger, S. N., Sequist, L. V.  
AMER SOC CLINICAL ONCOLOGY.2014
- **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.** *Nature medicine*  
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al

2014; 20 (5): 548-554

- **An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage** *NATURE MEDICINE*  
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., Shrager, J. B., Loo, B. W., Alizadeh, et al  
2014; 20 (5): 552-558
- **Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.** *Clinical lung cancer*  
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., Neal, J. W., Wakelee, H. A.  
2014; 15 (3): 202-206
- **Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.** *Immunopharmacology and immunotoxicology*  
Riess, J. W., Bhattacharya, N., Blenman, K. R., Neal, J. W., Hwang, G., Pultar, P., San-Pedro Salcedo, M., Engleman, E., Lee, P. P., Malik, R., Wakelee, H. A.  
2014; 36 (2): 182-186
- **A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.** *British journal of cancer*  
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., Leighl, N. B., Riess, J. W., Kuo, C. J., Liu, L., Gao, B., DiCioccio, A. T., Adjei, et al  
2014; 110 (3): 602-608
- **Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.** *Archives of pathology & laboratory medicine*  
Cagle, P. T., Sholl, L. M., Lindeman, N. I., Alsabeh, R., Divaris, D. X., Foulis, P., Lee, G., Neal, J. W., Nowak, J. A., Yu, P. P.  
2014; 138 (2): 171-174
- **A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer.**  
Jahchan, N., Joel, D., Mazur, P., Neal, J., Khatri, P., Butte, A., Sage, J.  
AMER ASSOC CANCER RESEARCH.2014
- **Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips** *LAB ON A CHIP*  
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., Schwartz, E. J., Weissman, I. L., Jeffrey, et al  
2014; 14 (1): 78-88
- **Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.** *Lab on a chip*  
Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., Schwartz, E. J., Weissman, I. L., Jeffrey, et al  
2013; 14 (1): 78-88
- **ENERGY METABOLISM IN LUNG ADENOCARCINOMA**  
Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., Das, M., Neal, J. W., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2013: S1036-S1037
- **ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION**  
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2013: S1185-S1186
- **PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER**  
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, et al  
LIPPINCOTT WILLIAMS & WILKINS.2013: S1324
- **VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS**  
Nguyen, K. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., Burt, B., Tisch, A., Pagtama, J., Zehnder, J., Berry, G., Wakelee, H. A., Anh-Hoa Nguyen, et al  
LIPPINCOTT WILLIAMS & WILKINS.2013: S208-S209

- **FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)**  
Soria, J., Sequist, L. V., Gadgeel, S., Goldman, J., Wakelee, H., Varga, A., Fidias, P., Wozniak, A. J., Neal, J. W., Doebele, R. C., Garon, E. B., Jaw-Tsai, S., Caunt, et al  
LIPPINCOTT WILLIAMS & WILKINS.2013: S141–S142
- **STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES**  
Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., Neal, J. W.  
LIPPINCOTT WILLIAMS & WILKINS.2013: S731
- **GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)**  
Riess, J. W., West, R., Padda, S. K., Dean, M., Klimowicz, A., Huong, C., Neal, J. W., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2013: S944
- **CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)**  
Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H. L., Subramaniam, D., Leach, J. W., Lara, P. N., Wax, M. B., Wakelee, H. A., Clary, et al  
LIPPINCOTT WILLIAMS & WILKINS.2013: S1072–S1073
- **Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. *Translational lung cancer research***  
Neal, J. W., Sequist, L. V.  
2013; 2 (5): 411-414
- **Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing**  
Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., Shrager, J., Loo, B. W., Alizadeh, A. A., Diehn, M.  
ELSEVIER SCIENCE INC.2013: S92
- **A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. *Clinical lung cancer***  
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., Cherry, A., Wakelee, H. A.  
2013; 14 (5): 592-595
- **GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)**  
Riess, J., West, R., Padda, S., Dean, M., Klimowicz, A., Huong, C., Neal, J., Wakelee, H.  
LIPPINCOTT WILLIAMS & WILKINS.2013: 25
- **STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES**  
Wakelee, H., Riess, J., Pedro-Salcedo, M., Padda, S., Ramchandran, K., Gubens, M., Neal, J.  
LIPPINCOTT WILLIAMS & WILKINS.2013: 22–23
- **First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.**  
Sequist, L. V., Soria, J., Gadgeel, S. M., Wakelee, H. A., Camidge, D., Varga, A., Fidias, P., Wozniak, A. J., Neal, J. W., Doebele, R., Garon, E. B., Jaw-Tsai, S. S., Stern, et al  
AMER SOC CLINICAL ONCOLOGY.2013
- **A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK***  
Riess, J. W., Nagpal, S., Neal, J. W., Wake, H. A.  
2013; 11 (4): 389-394
- **A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. *Journal of thoracic oncology***  
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.  
2013; 8 (2): e17-8
- **A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab *JOURNAL OF THORACIC ONCOLOGY***

- Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.  
2013; 8 (2): E17-E18
- **Aflibercept in lung cancer** *EXPERT OPINION ON BIOLOGICAL THERAPY*  
Neal, J. W., Wakelee, H. A.  
2013; 13 (1): 115-120
  - **Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.** *Journal of thoracic oncology*  
Riess, J. W., Neal, J. W.  
2012; 7 (16): S385-6
  - **MET inhibitors in combination with other therapies in non-small cell lung cancer.** *Translational lung cancer research*  
Padda, S., Neal, J. W., Wakelee, H. A.  
2012; 1 (4): 238-253
  - **Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer** *54th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*  
Bratman, S. V., Eclow, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., Richardson, K., Newman, A. M., Alizadeh, A., Diehn, M.  
ELSEVIER SCIENCE INC.2012: S713-S713
  - **A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*  
Goldberg, S. B., Supko, J. G., Neal, J. W., Muzikansky, A., Digumarthy, S., Fidias, P., Temel, J. S., Heist, R. S., Shaw, A. T., McCarthy, P. O., Lynch, T. J., Sharma, S., Settleman, et al  
2012; 7 (10): 1602-1608
  - **Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era**  
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Neal, J. W., Wakelee, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2012: S243-S243
  - **The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC)**  
Neal, J. W., Pennell, N. A., Govindan, R., Heist, R. S., Shaw, A. T., Muzikansky, A., Janne, P. A., Lynch, T. J., Azzoli, C. G., Sequist, L. V.  
LIPPINCOTT WILLIAMS & WILKINS.2012: S209-S209
  - **A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours** *BRITISH JOURNAL OF CANCER*  
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R., Colevas, A. D., Shepherd, F. A., Leighl, N. B., Neal, J. W., Thibault, A., Liu, L., Lisano, J., Gao, B., Lawson, et al  
2012; 107 (4): 604-611
  - **Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer** *JOURNAL OF CLINICAL ONCOLOGY*  
Neal, J. W., Sequist, L. V.  
2012; 30 (18): 2280-2282
  - **Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study** *JOURNAL OF CLINICAL ONCOLOGY*  
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J., Reck, M.  
2012; 30 (17): 2046-2054
  - **A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*  
Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., Leighl, N. B., Liu, L., Lisano, J. M., Adjei, A. A., Wakelee, H. A.  
AMER SOC CLINICAL ONCOLOGY.2012
  - **The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*  
Neal, J. W., Pennell, N. A., Govindan, R., Lanuti, M., Rosovsky, R. P., Heist, R. S., Shaw, A. T., Temel, J. S., Muzikansky, A., Janne, P. A., Lynch, T. J., Azzoli, C. G., Sequist, et al  
AMER SOC CLINICAL ONCOLOGY.2012
  - **First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.** *Biologics : targets & therapy*

Nguyen, K. H., Neal, J. W.  
2012; 6: 337-345

- **Current Management of Small Cell Lung Cancer** *CLINICS IN CHEST MEDICINE*  
Neal, J. W., Gubens, M. A., Wakelee, H. A.  
2011; 32 (4): 853-?
- **Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*  
Riess, J. W., Neal, J. W.  
2011; 6 (11): S1797-S1798
- **Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC**  
Heist, R. S., Duda, G. D., Sahani, D., Ancukiewicz, M., Fidas, P., Sequist, L. V., Shaw, A. T., Temel, J. S., Lennes, I. T., Neal, J. W., Pennell, N. A., Lynch, T. J., Engelman, et al  
AMER SOC CLINICAL ONCOLOGY.2011
- **One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer** *CLINICAL CANCER RESEARCH*  
Neal, J. W., Shaw, A. T.  
2011; 17 (4): 638-639
- **Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC** *ONCOLOGIST*  
Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Baldini, E. H., Choi, N. C., Willers, H., Jackman, D. M., Sequist, L. V.  
2011; 16 (6): 886-895
- **The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer** *FUTURE ONCOLOGY*  
Neal, J. W.  
2010; 6 (12): 1827-1832
- **Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.** *Journal of thoracic oncology*  
Neal, J. W., Heist, R. S., Fidas, P., Temel, J. S., Huberman, M., Marcoux, J. P., Muzikansky, A., Lynch, T. J., Sequist, L. V.  
2010; 5 (11): 1855-1858
- **AMG-386, a selective angiotensin-1/2-neutralizing peptidomimetic for the potential treatment of cancer** *CURRENT OPINION IN MOLECULAR THERAPEUTICS*  
Neal, J., Wakelee, H.  
2010; 12 (4): 487-495
- **Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*  
Neal, J. W., Sequist, L. V.  
2010; 11 (1-2): 36-44
- **Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.** *Nature reviews. Clinical oncology*  
Neal, J. W., Sequist, L. V.  
2010; 7 (2): 71-72
- **First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.** *Clinical advances in hematology & oncology : H&O*  
Neal, J. W., Sequist, L. V.  
2010; 8 (2): 119-126
- **Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells** *BLOOD*  
Barry, S. M., Zisoulis, D. G., Neal, J. W., Clipstone, N. A., Kansas, G. S.  
2003; 102 (5): 1771-1778
- **A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Neal, J. W., Clipstone, N. A.  
2003; 278 (19): 17246-17254
- **Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Neal, J. W., Clipstone, N. A.  
2002; 277 (51): 49776-49781



- **Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Neal, J. W., Clipstone, N. A.  
2001; 276 (5): 3666-3673
- **REGULATION OF THE GLUCOSE-H<sup>+</sup> SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS** *JOURNAL OF BACTERIOLOGY*  
Ye, J. J., Neal, J. W., Cui, X. W., Reizer, J., Saier, M. H.  
1994; 176 (12): 3484-3492